8-K: QT Imaging Q3 Revenue Soars, Reaffirms 2025 Forecast

QT Imaging Holdings, Inc. reported strong third-quarter 2025 financial results with record revenue of $4.2 million, reaffirming its full-year 2025 revenue and scanner shipment forecasts.

Summary

• Generated record revenue of $4.2 million in Q3 2025, representing 339% year-over-year growth and 15% sequential quarter-over-quarter growth.
• Shipped nine QTI Breast Acoustic CT scanners during the third quarter of 2025.
• Reaffirmed the 2025 forecast of $18 million in revenue and shipping a total of 40 scanners.
• Increased the 2026 revenue outlook from $27 million (60 scanners) to $39 million (80 scanners) due to a new distribution agreement for Saudi Arabia.
• Significantly strengthened the financial position through a fully subscribed $18 million private placement financing (October PIPE) with high-conviction healthcare specialist investors.
• Applied to relist on the Nasdaq Capital Market and completed a 3:1 reverse stock split, effective October 23, 2025, to meet listing requirements.
• Appointed Jay Jennings as the new Chief Financial Officer and Satrajit Misra as the Chief Commercial Officer.
• Entered into an exclusive distribution agreement with Gulf Medical Co. for Saudi Arabia.
• Launched the latest QTviewer, version 2.8, designed to enhance clinical efficiency and diagnostic accuracy.
• Reported a net loss of $4.6 million, or $(0.47) per share, for the third quarter of 2025.
• Non-GAAP Adjusted EBITDA was $(1.4) million for the third quarter of 2025.
• Cash as of September 30, 2025, was $1.7 million, not including the $18.2 million gross proceeds from the October 2025 PIPE financing.

Sentiment

Score: 7

Explanation: The company reported strong revenue growth and reaffirmed/increased future guidance, indicating positive operational momentum. Strategic hires, a significant capital raise, and global expansion efforts are strong positives. However, a decline in gross margin and an increase in net loss, along with an acknowledged material weakness in internal controls, temper the overall sentiment.

Positives

• Achieved record revenue of $4.2 million in Q3 2025, demonstrating substantial growth of 339% year-over-year and 15% sequentially.
• Reaffirmed the strong 2025 revenue forecast of $18 million and 40 scanner shipments, indicating consistent performance against projections.
• Significantly increased the 2026 revenue outlook from $27 million to $39 million, with scanner shipments projected to rise from 60 to 80 units, driven by new market expansion.
• Successfully completed an $18.2 million PIPE transaction, substantially strengthening the balance sheet and providing capital for expansion.
• Repurchased in full a warrant held by YA II PN, Ltd. for 5,000,071 shares, reducing potential future dilution.
• Expanded global reach with a new exclusive distribution agreement with Gulf Medical Co. for Saudi Arabia.
• Appointed two highly experienced executives, Jay Jennings as CFO and Satrajit Misra as CCO, bringing significant industry expertise to the leadership team.
• Launched QTviewer, version 2.8, enhancing product capabilities and clinical utility for customers.
• Submitted an application to relist on the Nasdaq Capital Market, which could improve market visibility and liquidity.
• Formed a strategic collaboration with Intelerad Medical Systems to deploy PACS and Cloud PACS, supporting the QTI Cloud SaaS Platform.
• Improved net cash used in operating activities to $(0.9) million in Q3 2025 from $(1.9) million in Q3 2024, indicating better operational cash management.
• Non-GAAP Adjusted EBITDA improved to $(1.4) million in Q3 2025 from $(2.2) million in Q3 2024.

Negatives

• Gross margin declined to 43% in Q3 2025 from 63% in Q3 2024, primarily due to variability in the weighted average cost of existing inventory.
• Total operating expenses increased by 18% to $3.5 million in Q3 2025 compared to $2.9 million in Q3 2024, driven by increases in professional services, employee compensation, and general business expenses.
• Net loss increased to $4.6 million in Q3 2025 from $3.6 million in Q3 2024, influenced by changes in the fair value of warrant and earnout liabilities and interest expense.
• The company has an identified material weakness in its internal controls over financial reporting, as noted in the forward-looking statements.

Risks

• The ability to successfully sell and deploy the QT Imaging Breast Acoustic CT Scanner.
• The ability to extend product offerings into new areas or products.
• The ability to commercialize technology effectively.
• Unexpected occurrences that could deter the full documentation and market launch plan for products.
• Trends and fluctuations in the industry that may impact demand.
• Changes in demand and purchasing volume from customers.
• Unpredictability of suppliers and potential supply chain disruptions.
• The ability to attract and retain qualified personnel and scale product sales to production levels.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• The inherent uncertainty of projected financial information.
• Potential delays caused by factors outside of the company's control.
• Changes in the ability to successfully receive purchase orders and generate revenue under existing contracts with partners and distributors.
• The ability to fully realize the benefits of strategic partnerships.
• The identified material weakness in internal controls over financial reporting and the timeline for its remediation.
• Risks associated with the rollout of the business and the timing of expected business milestones.
• The effects of competition on future business performance.
• The ability to obtain and access financing in the future.
• The ability to meet debt obligations as they come due.

Future Outlook

The company reiterates its plan to deliver $18 million in revenue and ship 40 scanners in full-year 2025. Due to a new agreement for Saudi Arabia, the 2026 revenue outlook has been increased from $27 million to $39 million, with scanner shipments projected to increase from 60 to 80 units. The company continues its transformation into a scalable imaging platform through the convergence of quantitative ultrasound, AI/ML, and biomarker science, aiming to create an intelligent, adaptive ecosystem for breast imaging.

Management Comments

• "I am pleased to report that our team delivered another strong performance. This quarter's results both underscore the strength of our current scanner business and provide a solid foundation for our continued transformation into a scalable imaging platform through the convergence of quantitative ultrasound, AI/ML, and biomarker science – creating an intelligent, adaptive ecosystem for breast imaging that continuously learns and improves with every patient scanned." Dr. Raluca Dinu, Chief Executive Officer.
• "We were also thrilled to recently welcome Jay Jennings as our new Chief Financial Officer, and Satrajit Misra as our first-ever Chief Commercial Officer. Combined, these two executive leaders bring close to 60 years of relevant, impactful experience to QT Imaging. On a personal note, through my work with Jay over the past months, and with Satrajit via our ongoing strategic partnership with Canon Medical Systems USA, they have both earned my trust, respect and most importantly, confidence. We look forward to their contributions to our execution and growth." Dr. Raluca Dinu, Chief Executive Officer.

Industry Context

QT Imaging is pivoting from a pure scanner company to a SaaS and biomarker-driven medical imaging franchise, aligning with broader industry trends towards integrated, intelligent, and data-driven healthcare solutions. The focus on quantitative ultrasound, AI/ML, and biomarker science positions the company in the growing market for advanced diagnostic tools, particularly for breast imaging, offering radiation-free, contrast-free, and compression-free alternatives which address patient safety and comfort concerns prevalent in traditional methods. The global expansion into Saudi Arabia also reflects the increasing demand for advanced medical technologies in emerging markets.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry.
• The company's focus on radiation-free, contrast-free, and compression-free breast imaging technology positions it as an alternative to traditional mammography and MRI, which are industry standards but come with limitations such as radiation exposure, contrast agent risks, and discomfort.
• The pivot towards a SaaS and biomarker-driven platform, integrating AI/ML, aligns with the broader medical imaging industry's trend towards digital transformation and precision medicine, aiming to enhance diagnostic accuracy and clinical efficiency.

Management Changes

Corporate Governance

Related Party Transactions

• Received $5.0 million in additional financing via a restated and amended senior secured term loan with Lynrock Lake Master Fund LP.
• Repaid $5.0 million of its restated and amended senior secured term loan with Lynrock Lake using proceeds from the October PIPE.
• The October PIPE included anchoring from Sio Capital and participation from other institutional and existing company investors.

Stakeholder Impact

• Shareholders: Potential for increased share price stability and liquidity if Nasdaq relisting is successful. The reverse stock split impacts share count and price per share. Dilution from the PIPE transaction is offset by a strengthened balance sheet.
• Customers: Enhanced product features with QTviewer 2.8 and seamless integration with Intelerad's PACS through the QTI Cloud Platform. Expanded access to QTI Breast Acoustic CT scanners in new regions like Saudi Arabia.
• Employees: New executive appointments (CFO, CCO) signal growth and strategic direction, potentially boosting morale and providing leadership.
• Creditors: Repayment of $5.0 million of the Lynrock Lake term loan reduces debt obligations.
• Partners: New distribution agreement with Gulf Medical Co. and strategic collaboration with Intelerad Medical Systems expand market reach and technological integration.

Next Steps

• Host a conference call on November 11, 2025, at 4:30 PM EST to discuss Q3 2025 results.
• Chief Medical Officer, Elaine Iuanow, MD, will host an in-person seminar at RSNA 2025 (November 30 December 4, 2025) titled "Quantitative Transmission Imaging Technology: The Future of Breast Imaging with Safe Volumetric Ultrasound."
• Exhibit at Booth #6713 at RSNA 2025 for live demonstrations of the FDA-cleared QTI Breast Acoustic CT scanner.
• Continue efforts to relist on the Nasdaq Capital Market.
• Expand U.S. and global go-to-market activities.
• Deploy the QTI Cloud Platform.

Key Dates

Recommendation

While QT Imaging demonstrated strong revenue growth and a significantly improved financial position through a successful PIPE, the decline in gross margin and increased net loss are areas of concern. The strategic pivot towards a SaaS and biomarker model, coupled with new executive hires and global expansion, presents a compelling long-term vision. However, the company is still in a growth phase with ongoing losses and an acknowledged material weakness in internal controls. The Nasdaq relisting and increased 2026 guidance are positive catalysts, but the stock's performance will heavily depend on successful execution of these initiatives and improvement in profitability metrics. A "hold" recommendation allows investors to observe the company's progress in addressing profitability challenges and realizing its strategic vision without taking on immediate new risk or divesting from potential future upside.

Keywords

QT Imaging, Breast Acoustic CT, Medical Device, Q3 2025 Earnings, Financial Results, SaaS, Biomarker, Medical Imaging, Nasdaq Relisting, Private Placement, Distribution Agreement, Saudi Arabia, CFO Appointment, CCO Appointment, Quantitative Ultrasound, AI/ML, Radiation-free Imaging, Compression-free Imaging